Omadacycline for Community-Acquired Bacterial Pneumonia

2019218 citationsJournal Articlebronze Open Access

Authors

Roman Stets

Monica Popescu · Clinical Emergency Hospital Bucharest

Joven Gonong · Lung Center of the Philippines

Ismail Mitha

William Nseir · Bar-Ilan University

Andrzej Madej · Andrzej Frycz Modrzewski Krakow University

Courtney Kirsch · Paratek Pharmaceuticals (United States)

Anita Das

Abstract

Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults. (Funded by Paratek Pharmaceuticals; OPTIC ClinicalTrials.gov number, NCT02531438 .).

Topics & Keywords

Pneumonia and Respiratory Infections Antibiotic Resistance in Bacteria Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 6, pp. 517-527

DOI: 10.1056/nejmoa1800201

Field-Weighted Citation Impact: 19.93